HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) CME: Take the course for this article: Volume 69, Number 17, October 23, 2007 Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slee, M. Articles by Donaghy, M. Search for Related Content PubMed PubMed Citation Articles by Slee, M. Articles by Donaghy, M. Related Collections All Clinical Neurology

Multifocal motor neuropathy

The diagnostic spectrum and response to treatment

From the Departments of Clinical Neurology (M.S., M.D.) and Clinical Neurophysiology (A.S.), University of Oxford, Radcliffe Infirmary, Oxford, UK.

Address correspondence and reprint requests to Dr. Michael Donaghy, Department of Clinical Neurology, University of Oxford, West Wing, John Radcliffe Hospital, Oxford OX3 9DU, UK joanna.wilkinson{at}clneuro.ox.ac.uk

Objective: To define the clinical spectrum in a large cohort of patients with multifocal motor neuropathy (MMN) and the effectiveness of IVIg treatment. We also test two neurophysiologic criteria for conduction block (CB) for relevance to treatment responsiveness.

Methods: Retrospective case cohort analysis of 47 patients with MMN followed for up to 12 years.

Results: A total of 32 (70%) had an upper-limb onset with most showing clinical features of conduction block: weakened but non-wasted muscles (67%) and differential weakness across muscles supplied by a common terminal motor nerve (54%). Differential weakness of finger extension was a characteristic early sign. Application of consensus criteria for definite CB would have denied a trial of treatment to 6 patients with a typical phenotype compared with new criteria. No association was found between CB and presence of anti-GM1 ganglioside antibody. A total of 24 (51%) patients were treated with IVIg, which was associated with a marked initial improvement in self-reported disability in most patients. The magnitude of initial disability improvement was not sustained in all patients over time. However, the majority of treated patients reported significantly less disability at last follow-up than prior to treatment. Patients converted to a domiciliary IVIg program maintained function at least as well as hospital treated patients.

Conclusion: The importance of the clinical phenotype of multifocal motor neuropathy (MMN) is emphasized. Neither conduction block (CB) nor antibody status is a reliable predictor of treatment responsiveness. Over-reliance upon consensus CB criteria can deny IVIg to patients with MMN who are treatment responsive.

GLOSSARY: AAEM = American Academy of Electrodiagnostic Medicine; CB = conduction block; CBcc = consensus criteria; CBnc = new criteria; CMAP = compound muscle action potential; LL = lower limb; MMN = multifocal motor neuropathy; NS = not significant; SNAP = sensory nerve action potential amplitude.

Supplemental data at www.neurology.org

Disclosure: The authors report no conflicts of interest.

Received December 14, 2006. Accepted in final form May 8, 2007.

This article has been cited by other articles:

				M. Stangel Review: New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins Therapeutic Advances in Neurological Disorders, September 1, 2008; 1(2): 115 - 124. [Abstract] [PDF]

				Y A Rajabally Multifocal motor neuropathy: review of a treatable immune mediated disorder Postgrad. Med. J., June 1, 2008; 84(992): 287 - 292. [Abstract] [Full Text] [PDF]